Mereo BioPharma Shares Dip on Downgrade and Study Concerns

Mereo BioPharma shares are trading lower after Needham downgraded its price target from $7 to $5. The downgrade follows the company's announcement that the Phase 3 Orbit study missed its second interim analysis, raising concerns over setrusumab's progress.